Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-08EMA Authorised: Fycompa (perampanel) — Eisai GmbH
The European Medicines Agency authorised Fycompa (perampanel) by Eisai GmbH for partial-onset seizures in epilepsy.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation study of cenobamate in pediatric patients with partial-onset seizures. The st…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures [Phase 4]
Phase 4 clinical trial update on the pharmacokinetics, safety, and tolerability of ZONISADE in children aged 1 month to 17 years with partia…
-
FDA approval · 2026-02-24FDA Approved: PREGABALIN — Original Application (FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED)
FDA approved the original Abbreviated New Drug Application for pregabalin from Fourrts (India) Laboratories Private Limited, granting a gene…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM ORAL SOLUTION — Original Application (Ascend Laboratories, LLC)
The FDA approved an original application for a generic brivaracetam oral solution from Ascend Laboratories, enabling a generic formulation f…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for a generic version of brivaracetam. The generic is approved for the treatment of partial…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original abbreviated new drug application for a generic Brivaracetam product from Novadoz Pharmaceuticals LLC. Brivaracetam…
-
FDA approval · 2026-02-23FDA Approved: BRIVARACETAM — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' generic version of brivaracetam through an original ANDA, expanding access to an antiseizure medicat…
-
FDA approval · 2026-01-30FDA Approved: BRIVARACETAM — Supplemental Application (SolarisPharmaCorporation)
The FDA approved a supplemental application for brivaracetam from SolarisPharmaCorporation, signaling regulatory action to update the drug's…
-
FDA approval · 2026-01-29FDA Approved: LACOSAMIDE ORAL SOLUTION — Original Application (Florida Pharmaceutical Products, LLC)
FDA approved the original application for Lacosamide Oral Solution from Florida Pharmaceutical Products, LLC, adding a generic formulation f…
-
FDA approval · 2026-01-21FDA Approved: LACOSAMIDE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Glenmark Pharmaceuticals' lacosamide original application, authorizing a generic lacosamide product. Lacosamide is used for the…
-
FDA label_change · 2025-12-29FDA Approved: PREGABALIN — Supplemental Application (Cipla USA, Inc.)
FDA approved a supplemental application for Pregabalin submitted by Cipla USA, Inc., indicating changes to the drug's labeling. The notice d…
-
FDA approval · 2025-11-25FDA Approved: PERAMPANEL — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved the original application for a generic form of perampanel from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2025-10-15FDA Approved: LACOSAMIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for lacosamide, a generic anticonvulsant, under the ANDA framework. The notice…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy [Phase 2]
A Phase 2 study evaluating the efficacy and safety of Perampanel as adjunctive therapy in pediatric epilepsy with partial-onset seizures; re…
-
FDA approval · 2025-09-17FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Oxcarbazepine filed by Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2025-09-17FDA Approved: PREGABALIN — Supplemental Application (MARKSANS PHARMA LIMITED)
The FDA approved a supplemental application for pregabalin from Marksans Pharma Limited, resulting in approval of a generic pregabalin produ…
-
CLINICAL_TRIALS withdrawal · 2025-09-15Clinical Trial Update: An Extended Access Program (EAP) for Perampanel
The extended access program for perampanel has ended and is no longer available.
-
FDA approval · 2025-08-28FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approves a supplemental application for Briviact (brivaracetam) from UCB, Inc., resulting in labeling updates for the product.
-
FDA approval · 2025-08-28FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc.
-
FDA approval · 2025-08-21FDA Approved: PREGABALIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental ANDA for pregabalin, authorizing the marketing of a generic pregabalin product.
-
FDA approval · 2025-08-21FDA Approved: PREGABALIN — Supplemental Application (ScieGen Pharmaceuticals, Inc)
FDA approved a supplemental application for pregabalin from ScieGen Pharmaceuticals, Inc., confirming approval of the generic product under …
-
FDA approval · 2025-08-18FDA Approved: PREGABALIN — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Pregabalin submitted by Rising Pharma Holdings, Inc. under the approved ANDA.
-
FDA approval · 2025-08-15FDA Approved: PREGABALIN — Supplemental Application (Indoco Remedies Limited)
FDA approved a supplemental application for pregabalin from Indoco Remedies Limited, resulting in approval of a generic pregabalin product.
-
FDA approval · 2025-07-21FDA Approved: PREGABALIN — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' supplemental application for pregabalin. The approval enables the marketing of a generic pregabalin pr…